Lyra Therapeutics (LYRA) Stock Price, News & Analysis

Company Overview

Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS). LYR-210 is currently advancing through pivotal Phase 3 clinical trials, following positive Phase 2 data demonstrating significant improvements in symptom control and quality of life measures. In addition, Lyra is developing LYR-220 for chronic obstructive pulmonary disease (COPD) and exploring other respiratory indications, all based on its sustained-release implant technology.

Founded in 2015 and headquartered in Lynnfield, Massachusetts, Lyra Therapeutics operates research and development facilities in the United States. The company is led by President and Chief Executive Officer Bryan J. Bork, supported by a management team with extensive expertise in drug delivery, drug development and regulatory strategy. As Lyra advances its pipeline through clinical development, it seeks to establish partnerships for commercial manufacturing and expand its platform into additional ENT and respiratory disease areas.

Key Stats

• Today's Range: $0.20 to $0.20
• 50-Day Range: $0.00 to $0.71
• 52-Week Range: $0.00 to $8.75
• Volume: 261 shs
• Average Volume: 1,227 shs
• Market Capitalization: $354 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Lyra Therapeutics Stock Analysis - MarketRank™

Lyra Therapeutics scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Lyra Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Lyra Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lyra Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lyra Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.29% of the float of Lyra Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lyra Therapeutics has a short interest ratio ("days to cover") of 1.87, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lyra Therapeutics has recently increased by 0.02%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lyra Therapeutics does not currently pay a dividend.

Dividend Growth

Lyra Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lyra Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.25% of the stock of Lyra Therapeutics is held by insiders.

Percentage Held by Institutions

95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/12/2025
• Today: 8/29/2026
• Next Earnings (Estimated): 8/31/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:LYRA
• Previous Symbol: NASDAQ:LYRA
• CIK: 1327273
• Web: www.lyratherapeutics.com
• Phone: 617-393-4600
• Fax: N/A
• Employees: 50
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): ($19.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.92 million
• Net Margins: -7,266.08%
• Pretax Margin: -7,263.32%
• Return on Equity: N/A
• Return on Assets: -59.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.71
• Quick Ratio: 1.71

Sales & Book Value

• Annual Sales: $400 thousand
• Price / Sales: 0.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($6.04) per share
• Price / Book: -0.03

Miscellaneous

• Outstanding Shares: 1,770,000
• Free Float: 1,717,000
• Market Cap: $354 thousand
• Optionable: No Data
• Beta: 0.72